A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
Status:
Not yet recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
This is a research study to find out if a drug called belantamab mafodotin in combination
with dexamethasone, a steroid, can be safely and effectively given in the community setting.
Belantamab mafodotin (BLENREP) was approved in the US in August 2020 under an FDA program
called accelerated approval. In November 2022, belantamab mafodotin was removed from the
market because a study to further confirm its activity in relapsed/refractory multiple
myeloma did not deliver a supporting result. However, this confirmatory study demonstrated
that some patients may still benefit from treatment with belantamab mafodotin, and that this
benefit can be long lasting. Belantamab mafodotin is often given at large academic medical
centers every 3 weeks. This study will assess whether it is possible to administer belantamab
in the community setting every 6 weeks. It is unknown if administering belantamab every 6
weeks versus every 3 weeks will result in improved safety and/or reduced efficacy.